Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Medikidz

    - PMLiVE

    North East and North Cumbria NHS rolls out digital health platform to combat chronic kidney disease, affecting 1 in 10 UK adults

    In a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria Integrated Care Board (ICB) has adopted the Healthinote digital health platform, providing...

    Healthinote (by Cognitant)

    - PMLiVE

    Bridging the gap in personalised digital support: My Stroke Companion

    To empower stroke survivors to engage with their care, Cognitant, in partnership with University College London Hospitals (UCLH), identified a need for a new digital health companion that can support...

    Healthinote (by Cognitant)

    - PMLiVE

    Kidney Research UK invests in Healthinote patient education platform which could support >15m people with long term health conditions

    Kidney Research UK, the leading charity dedicated to kidney health, has made a significant investment in Cognitant Group Ltd, a leading provider of digital education and support tools to improve...

    Healthinote (by Cognitant)

    - PMLiVE

    Health literacy & the creation of shared decision aids for patients with cancer

    In this blog, Gini Melesi, Head of Transformation, East of England Cancer Alliance, & Diane Whitney, Head of Brachytherapy Physics, Cambridge University Hospitals NHS Foundation Trust, explore the relationship between...

    Healthinote (by Cognitant)

    - PMLiVE

    AstraZeneca shares late-stage results for Airsupra in mild asthma patients

    More than ten million asthma exacerbations occur in the US every year

    - PMLiVE

    AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

    Up to 262 million people worldwide are affected by the chronic respiratory disease

    - PMLiVE

    Chiesi report highlights incorrect inhaler use among UK asthma patients

    The long-term lung condition affects around 7.2 million people in the UK

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    UK researchers uncover first new asthma and COPD attack treatment in 50 years

    The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

    - PMLiVE

    AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra

    The chronic respiratory disease is estimated to affect up to 262 million people globally

    - PMLiVE

    GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition

    The deal includes a monoclonal antibody ready to enter phase 2 development for asthma

    - PMLiVE

    AstraZeneca’s mild combination asthma reliever approved in UK

    Over two and a half million adults with mild cases of asthma could be eligible for the treatment

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links